The market for exophthalmos treatment is anticipated to be valued USD 271.8 million, up from USD 251.2 million in fiscal year 2022. The worldwide market is anticipated to increase steadily between 2023 and 2033, increasing its value to USD 598 million by the end of that year.
Graves’ illness is most frequently to blame for exophthalmos. Ocular involvement will occur in about 25 to 50 percent of people with this condition. It’s noteworthy to note that ocular dysfunction may occur up to 20 years after the diagnosis of a thyroid problem or up to 10 years before. From 2023 to 2033, these disorders were a key factor in the exophthalmos therapy.
A research by Biomed Central Ltd, which was released in September 2020, found that the prevalence of exophthalmos illness patients worldwide was around 10.36% for hypothyroidism, 7.9% for euthyroidism, while 86.2% for hyperthyroidism. As a result, the rising incidence of exophthalmos illness among people is boosting market growth globally and is predicted to do so in the future, propelling the expansion of the studied market throughout the forecast period.
Region-wise, the North American region is expected to be the most lucrative market for exophthalmos diseases. According to figures from the American Academy of Ophthalmology that were published in July 2022, approximately 18 in 100,000 Americans suffer exophthalmos illness. At the same time, novel drug and treatment developments have also been pushing the regional market towards new heights. Such developments are expected to open up new opportunities for the regional manufacturers during the forecast period.
Key Takeaways from the Market Study
- The market for exophthalmos treatment expanded at a CAGR of 6.4% during the historical period of 2018 to 2022.
- The market for exophthalmos treatment is expected to grow steadily from 2023 to 2033, at a 8.2% CAGR.
- It is projected that the non-surgical segment by treatment type will dominate in 2023 with a 53% revenue share.
- With a 25% market share in 2023, the specialty clinic sector by end-user will hold the second-largest segment throughout the projected period.
- From 2023 to 2033, the North American region is expected to expand at a constant CAGR of 8.7%.
- From 2023 to 2033, the Asia Pacific exophthalmos treatment market is anticipated to expand at a stable CAGR of 7.1%.
“The increasing incidences of hyperthyroidism along with Graves’ disease have been accelerating the growth of the global exophthalmos market during the forecast period.” comments a Future Market Insights analyst.
Competitive Landscape
Some of the top players in the global exophthalmos disease market are:
- EyeBiotech Ltd.
- Eyevance Pharmaceuticals
- Sling Therapeutics
- Competition Deep Dive
- AbbVie
- Alcon
- Avik Pharma
- Anuh Pharma Ltd.
- Pfizer CentreOne
- Pipelinepharma
- Mylan N.V.
- Manus Aktteva Biopharma LLP
- Roche
Some of the recent developments in this domain are:
- EyeBiotech Ltd., a privately owned ophthalmology biotechnology business seeking to develop a new generation of eye disease therapeutics, announced the successful conclusion of a $65 million Series A fundraising round in 2022. Samsara BioCapital, Jeito Capital, and SV Health Investors spearheaded the round, with additional funding provided by MRL Ventures. A multinational team of executives as well as investors with a long history of creating ground-breaking ophthalmology medicines are brought together for the Series A.
More Insights Available
FMI, in its new offering, presents an unbiased analysis of the global exophthalmos treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of treatment (non-surgical treatment and surgical treatment), by end-user (hospitals, specialty clinics and others) & region.
Key Segments Covered In The Exophthalmos Treatment Market Report
Exophthalmos Treatment Market By Treatment:
- Non-surgical Treatment
- Sympathomimetic Amines
- Corticosteroids
- Secondary Metabolites
- Monoclonal Antibodies
- Radiotherapy
- Surgical Treatment
- Orbital Decompression
- Eye Muscle Surgery
- Eyelid Surgery
Exophthalmos Treatment Market By End User:
- Hospital Pharmacies
- Specialty Clinics
- Others
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
